33 C
Vientiane
Friday, May 2, 2025
spot_img
Home Blog Page 364

Kavalan Releases Limited 15 Years Old Whisky from ‘Time Exploration’ Series

’15 Years Old Single Malt Whisky’ is Kavalan’s first age statement whisky

TAIPEI, March 11, 2025 /PRNewswire/ — Kavalan Distillery is launching its first-ever whisky with an age statement, matured in four unique casks: ex-Bourbon, Oloroso Sherry, Ruby Port, and Puncheon.

Kavalan unveils its first-ever age statement whisky, marking a new milestone in its journey through time and maturation.
Kavalan unveils its first-ever age statement whisky, marking a new milestone in its journey through time and maturation.

The release marks a milestone in the journey of this Taiwanese distiller, which has broken boundaries not just by region, but now also by time and maturation.

The whisky also pays tribute to the historic moment when Kavalan and Taiwan began whisky making. On this day in 2006, the first ever drops of Taiwanese-made new make spirit rolled off the stills, setting the stage for nearly two decades of innovation and craftsmanship.

Kavalan 15 Years Old Single Malt Whisky 2025 Edition, 43% ABV, 700ml will be released in just 30,000 bottles globally, representing rare stock from the subtropical distillery’s ultra-aged whisky selection.

One of Kavalan’s oldest bottlings, CEO Mr YT Lee said the 2025 edition has been masterfully blended using hand-selected aged whisky reserves, drawing on the four distinct cask types.

“We wanted to achieve extraordinary depth and balance with multiple layers of complexity befitting of a high-age statement whisky. So we created a formula based on a four-cask maturation that would maximise the characteristics of each cask and achieve a rich harmony in the final product,” he said.

A tribute to 15 years of mastery, Kavalan presents this whisky as a timeless classic, capturing the true nature of time and craftsmanship. The packaging design embodies natural wood grain, symbolising the depth and maturity gained through years of ageing. The bottle design reflects the concept of ‘fusion,’ harmoniously vatted from four cask types, with textured oak patterns representing their distinct characteristics. The gold-foiled Kavalan logo adds a touch of luxury and sophistication, perfectly encapsulating the refined depth of this 15-year-old whisky.

The Kavalan 15 Years Old Single Malt Whisky 2025 Edition is available through Kavalan’s official channels in Taiwan, including the Kavalan Distillery Shop, Kavalan Whisky shops, Kavalan Whisky Bar, and select local liquor stores. 

Kavalan 15 Years Old Single Malt Whisky (2025 Edition)

Celebrating 3/11, 2006, when Kavalan distilled Taiwan’s first new make spirit, this 15 Years Old Single Malt Whisky marks nearly two decades of craftsmanship.
Celebrating 3/11, 2006, when Kavalan distilled Taiwan’s first new make spirit, this 15 Years Old Single Malt Whisky marks nearly two decades of craftsmanship.

Product Description:

Kavalan 15 Years Old, 700ml 43% ABV whisky is a testament to Kavalan’s craftsmanship, showcasing the perfect balance of ageing, cask influence, and blending artistry in every sip.

Colour: Golden caramel

Nose: Captivating aromas of caramel apple mousse, fresh chocolate, walnut cinnamon rolls, and creamy popcorn, intertwined with subtle hints of dried tangerine peel and plum. The finish reveals the sweetness of toffee and black date fruit, evoking a warm, indulgent sweetness.

Palate: Lush citrus aromas of bergamot, lemon, orange, and grapefruit dance with the sweet whispers of dried cranberries, raisins, and longan, unfolding into velvety notes of dark chocolate gelato and caramel walnut coffee mousse. The finish lingers with the comforting warmth of woody cinnamon spice.

About Kavalan Whisky

Kavalan Distillery in Yilan County has been pioneering the art of single malt whisky in Taiwan since 2005. Our whisky, aged in intense humidity and heat, sources the crystal meltwaters of Snow Mountain and is enhanced by sea and mountain breezes. These conditions combine to create Kavalan’s signature creaminess. Taking Yilan County’s old name, our distillery is backed by about 45 years of beverage-making under parent company, King Car Group. We have collected 900 gold awards or higher from the industry’s most competitive contests.

Contact:
Kaitlyn Tsai
kaitlyn@kingcar.com.tw 

Britney Chen
britneychen@kingcar.com.tw 

IFF Extends Enviva® PRO Probiotic Range to Improve Swine Welfare

New studies reveal that the three-strain Bacillus probiotic can better protect weaned piglets against diverse health challenges.

SINGAPORE, March 11, 2025 /PRNewswire/ — IFF (NYSE:IFF) today announced the extension of their three-strain Bacillus probiotic, Enviva® PRO, to pigs. By incorporating IFF’s probiotic into their diet, producers will be better positioned to protect their animals against diverse health challenges. The extension of Enviva® PRO enhances IFF’s robust portfolio of proven, cost-effective animal nutrition and health solutions that help customers optimize production, livability and profitability.

“The weaning and post-weaning period can be extremely difficult to navigate for swine producers, so implementing a nutritional management strategy is crucial for improving their welfare and avoiding growth setbacks,” said Dr. Ester Vinyeta, swine innovation lead at IFF. “In addition to the proven benefits of Enviva® PRO already experienced by broiler producers, swine producers now can have peace of mind that their litters have optimal gut health – helping them meet growing production demands.”

Post-weaning, piglets may face challenges like nutritional stress, reduced feed intake, and digestive health issues, which can impact performance. Enviva® PRO is proven to establish and maintain a favorable nutribiotic state that supports optimal gut function, leading to improved nutrient digestion and performance. Extensive studies performed by IFF found that compared to the control group, Enviva® PRO improved average daily weight gain by 2.5% and reduced diarrhea frequency by 6.3%.

Enviva® PRO is currently available to swine producers across Japan and the US. IFF plans to extend availability to other territories following pending regulatory authorizations.

Learn more about the benefits of Enviva® PRO and nutribiosis in animal production at animalnutrition.iff.com/enviva-pro.

About Danisco Animal Nutrition & Health

Danisco Animal Nutrition & Health, part of IFF, is an industry leader in nutritional health solutions with a comprehensive portfolio of feed enzymes, betaine, essential oils and probiotics. Through the lens of nutribiosis, IFF invests in science and innovation to help producers improve performance, increase liveability and support welfare in the face of increasing pressure to reduce or remove antibiotics from production systems. Danisco Animal Nutrition & Health capabilities are underpinned by the quality and quantity of our trials, including over 100,000 guts sampled from over 600 farms, investments in omics technologies and microbiome research, and collaboration with leading commercial, governmental and academic partners. For more information, visit iff.com/animal-nutrition.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.comLinkedInInstagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Michael D. Patten as Chief Strategy Officer. Michael will be based in the United States and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

In this role, Michael will be responsible for formulating and overseeing the global corporate development and growth strategy for Harbour BioMed. In addition, as the Head of Global Alliance, he will lead efforts to manage and strengthen Harbour BioMed’s global strategic partner network and ecosystem, with a particular focus on high-potential markets outside of China, further enhancing Harbour BioMed’s global branding and presence.

Michael brings extensive experience and a strong track record in the biopharmaceutical industry. During his tenure at Bristol Myers Squibb, he held several key leadership roles. Most recently, as Head of Equity & Venture Capital, he led and managed significant numbers of strategic equity investments and LP commitments across the life science ecosystem. Prior, he held roles of increasing seniority in Business Development and Alliance Leadership, successfully executing transactions and managing multiple early- and late-stage business development alliances, demonstrating exceptional expertise in business development and alliance management.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are pleased to welcome Michael D. Patten as our Chief Strategy Officer. Harbour BioMed has always been committed to the discovery, development and commercialization of innovative biotherapeutics, striving to provide more effective treatment options to patients. Michael’s academic background and extensive experience align perfectly with our strategic direction. I am confident that with Michael’s expertise, we will further expand our global footprint and enhance the visibility and impact of Harbour BioMed.”

Michael D. Patten, Chief Strategy Officer of Harbour BioMed, added: “I am excited to join Harbour BioMed at such a pivotal time. The company’s innovative platforms and commitment to addressing unmet medical needs create tremendous potential. I look forward to driving strategic initiatives with existing and new partners that will accelerate growth globally and deliver impactful therapies to patients.”

Michael holds a Bachelor of Science with Joint Honors in Pharmacology & Business Studies from the University of Edinburgh, a Master of Science in Pharmaceutical Medicine from the University of Surrey, and an MBA from the University of Maastricht (EuroMBA Consortium).

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The proprietary antibody technology platform Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com

 

Eviden Launches Evidian Orbion: A Next-Generation, comprehensive Cloud- Based Identity and Access Management Solution

TOKYO, March 11, 2025 /PRNewswire/ — Eviden, the Atos Group business leading in digital, cloud, big data and security today announces the launch of Evidian Orbion, its next-generation Identity-as-a-Service (IDaaS) solution. Evidian Orbion integrates Identity Governance and Administration (IGA), Access Management (AM), and Privileged Access Management (PAM) into a single as-a-Service solution designed for hybrid environments. Evidian Orbion offers organizations a flexible, scalable way to manage identities and access rights, with a focus on efficiency and security.

Securing the extended enterprise 

For several years, companies had structured themselves around an internal security perimeter, protected by firewalls and VPNs. Today, employees and third-party partners need to access business applications, that may run outside of companies’ internal perimeter, from a variety of locations outside the company’s internal network. This identity-first security paradigm introduces a new level of complexity for identity and access management. Evidian Orbion focuses on reducing IAM deployment complexity and strengthens deployments with capacities like self-enrolment and integration with Identity Proofing tools. Evidian Orbion is built to scale for mid-market and large organizations.

Meeting enhanced regulatory and sovereignty requirements  

What’s more, the regulatory landscape like the European NIS 2 Directive, for example, extends security requirements, requiring companies to further formalize their risk analysis policies, speed up the processing and disclosure of vulnerabilities, improve the handling of security incidents, define access control policies, and deploy strong authentication. Evidian Orbion offers a secure and compliant IAM foundation, for governing access controls and implementing multi-factor authentication. The solution provides advanced capabilities like identity proofing, decentralized identities (SSI), and a highly secure infrastructure designed with DevSecOps.  

David Leporini, Director of IAM Cybersecurity Products & General Manager of Evidian, Eviden, Atos Group, said“Evidian Orbion simplifies IAM management by offering a cloud-native solution that reduces complexity and overhead for enterprises. In addition, the solution also provides essential IAM functionalities such as identity governance and access management, all in a scalable and flexible SaaS model. With Orbion, enterprises can manage identities across applications securely, ensuring compliance while seamlessly scaling to meet evolving business needs.” 

Martin Kuppinger, Principal Analyst & Co-founder, KuppingerCole Research said: “Evidian Orbion is a powerful solution in the Identity Fabrics market segment. With its deployment model, it is targeted at mid-market and large organizations, providing them the flexibility they need. Also, with Evidian being a European vendor and IDaaS deployment from EU data centers, the solution is well positioned for serving the needs of EU-based organizations that mandate or prefer sovereign solutions with EU data residency, such as governmental agencies and critical infrastructure companies.”

For more information about Evidian Orbion, please visit: https://www.evidian.com/products/orbion-identity-and-access-management-as-a- service-iam/

About Eviden1 

Eviden is a next-gen technology leader in data-driven, trusted and sustainable digital transformation with a strong portfolio of patented technologies. With worldwide leading positions in advanced computing, security, AI, cloud and digital platforms, it provides deep expertise for all industries in more than 47 countries. Bringing together 41,000 world-class talents, Eviden expands the possibilities of data and technology across the digital continuum, now and for generations to come. Eviden is an Atos Group company with an annual revenue of c. € 5 billion. 

About Atos

Atos is a global leader in digital transformation with c. 82,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris. 

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. 

1 Eviden business is operated through the following brands: AppCentrica, ATHEA, Cloudamize, Cloudreach, Cryptovision, DataSentics, Edifixio, Engage ESM, Evidian, Forensik, IDEAL GRP, In Fidem, Ipsotek, Maven Wave, Profit4SF, SEC Consult, Visual BI, X-Perion. Eviden is a registered trademark. © Eviden SAS, 2025. 

 

Logo: https://laotiantimes.com/wp-content/uploads/2025/03/eviden_logo.jpg

 

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 11, 2025 /PRNewswire/ — Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Dr. Ian Y. Liu as Senior Vice President, Global Head of Legal. Dr. Liu will be based in the U.S. and report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed.

With his extensive legal expertise and industry experience, Dr. Liu will oversee business development transactions, ensuring legal and regulatory compliance while facilitating seamless execution to safeguard the company’s interests. He will also lead the company’s global intellectual property strategy. Additionally, Dr. Liu will take full responsibility for managing U.S.-related legal affairs, including prosecution and litigation of all legal cases, protecting the company’s business operations in the region and supporting its strategic growth in the U.S. market.

Before joining Harbour BioMed, Dr. Liu worked at renowned law firms, including Finnigan, Henderson, Farabow, Garrett & Dunner, LLP, and K&L Gates, LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he held key positions such as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, demonstrating exceptional ability in handling complex legal matters and commercial negotiations.

Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: ” We are pleased to welcome Dr. Ian Y. Liu to Harbour BioMed. As we continue to expand our business globally, Dr. Liu’s expertise in intellectual property, business transactions, and regulatory affairs will be invaluable. With his extensive legal expertise and industry experience, we look forward to him playing a critical role in supporting the company’s sustained growth in the U.S. and international markets, further strengthening our industry position and global impact.”

Dr. Ian Y. Liu, Senior Vice President, Global Head of Legal of Harbour BioMed, added: “Harbour BioMed has always been at the forefront of drug discovery and development, business innovation, and globalization. It is a privilege and honor to become a member of Harbour BioMed and I am looking forward to contributing to Harbour BioMed’s bright future.”   

Dr. Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

The proprietary antibody technology platform Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice®, and HBICE® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies. For further information, please refer to www.harbourbiomed.com.

Impact X returns as marquee event of Climate Action Week Sydney

SYDNEY, March 11, 2025 /PRNewswire/ — Australia’s largest climate and nature summit Impact X returns for its fourth year as a marquee event of Climate Action Week Sydney, with 500+ attendees and 50+ speakers from across the globe converging on Sydney’s Town Hall today.

This year’s theme of “Towards a Climate Positive Future: Delivering Net Zero and Beyond” comes as record-breaking heatwaves and extreme weather events increase worldwide in a world warming beyond 1.5°C, including Ex-Tropical Cyclone Alfred.

Critically, this year’s will also strongly focus on the integration of indigenous and Pacific knowledge systems.

This includes kicking off with a panel featuring Dr Anne Poelina (Nyikina Warrwa Woman), Tui Shortland (Director, Te Kopu Pacific Indigenous & Local Knowledge Centre), and other First Nations leaders.

It will also be co-MCed by Susan Moylan-Coombs, Founding Director of the Gaimaragal Group, alongside Jeremy Liddle, Managing Director of Third Hemisphere.

Susan Moylan-Coombs will outline how indigenous knowledge systems represent untapped resources, given approaches such as the circular economy are actually age-old indigenous practices that could have been implemented hundreds of years ago.

Notable other speakers include keynotes from Clover Moore (Lord Mayor of Sydney), Matt Kean (Chair, Climate Change Authority), Johan Rockstrom (Potsdam Institute for Climate Impact Research), Dermot O’Gorman (CEO, WWF Australia), and Katie Kiss (Aboriginal & Torres Strait Islander Social Justice Commissioner).

Speakers focussed on the business community in particular include Kate Dundas, Executive Director at the UN Global Compact, Martijn Wilder AM, Chair of the National Reconstruction Fund, and Michael Battaglia, Mission Lead Towards Net Zero at CSIRO.

There will also be a special session featuring Keith Tuffley and Kat Bruce on their Ocean Science Expedition where they undertook a single-season crossing of the arctic Northwest Passage to raise awareness of  the six planetary tipping points in the arctic.

Event co-founder and director, Tony Gourlay, believes these conversations couldn’t be more urgent, as record-breaking heatwaves and extreme weather events worldwide provide a sobering preview of challenges in a world warming beyond 1.5°C.

Tony Gourlay, Co-founder and Director of Impact X said: “People from across all areas of society – whether in business, government, investment, or otherwise – are encouraged to attend this landmark event that promises to deliver debate, discussion, and lots of big ideas to accelerate investment and collaboration across sectors, borders, and all levels of society.”

Tim Ferraro, Director APAC at Land Life, said:: “Regardless of what is happening with the US withdrawing from the Paris Agreement, it’s all systems go in Australia from the perspective of nature restoration. If the US is scaling down, we’ve got other countries scaling up. It’s providing an opportunity to drive more international capital to restoration work closer to home. Global firms are still getting on with the job – we see large companies putting out very large tenders for nature-based restoration carbon offsets, with a big demand for high integrity projects.”

Michael Battaglia, Mission Lead Towards Net Zero at CSIRO, said: “Impact X will be again an important coming together.  We are now well into the net zero transition and some things are going well and some bits are proving hard.  But it is when things are hard and complex that we need to come together and learn from each other, and look at new ways to solve the hard problems.”

The Impact X Summit will be held at Sydney Town Hall on March 11, 2025, with tickets available here.

Impact X is Australia’s global climate conference organiser, bringing together industry, government, investors, and other stakeholders to catalyse solutions to climate change, restore the natural environment, and create the sustainable systems of the future. With its Impact X Summits, the company supports the growth and scaling of climate investment, technologies, and net zero innovation.

Third Hemisphere is a leading APAC-based PR and investment agency specialising in technology, finance, sustainability and climate, for innovators, leaders and investors who are breaking new ground and changing the world. Our mission is to help clients lead the conversation to create impact and become category leaders, through strategic and integrated communications across tier-1 news media, social, and digital channels. This drives commercial outcomes with their investors, customers, partners, talent, and governments. We also create and implement investment strategies and investor comms that drive the success of fast-growth technology ventures. Third Hemisphere was awarded 2024 Mumbrella PR Agency of the year, the 2023 Mumbrella Boutique Agency of the Year and 2023 SABRE Best Financial Services Campaign. Founder and Managing Director, Hannah Moreno, has also been awarded Mumbrella’s 2023 PR Professional of the Year, shortlisted for Mumbrella’s 2024 PR Leader of the Year, and was also finalist for 2023 PR Agency Head of the Year at the PR Asia Awards and the 2021 Women in Finance Awards.

Setouchi: A Vibrant Hub of Culture, Cuisine, and Experiences

SETOUCHI, Japan, March 11, 2025 /PRNewswire/ — The Setouchi region of Japan, made famous to an international audience by Donald Richie’s exceptional The Inland Sea — a travelogue which has inspired millions since its release in 1971, is a thriving cultural cornucopia. Comprising several prefectures, Setouchi is a stunning landscape and location to explore while traveling in Japan.

“Lord of Ozu Castle” experience
“Lord of Ozu Castle” experience

Hyogo Prefecture
Kobe Beef and Kobe Beef Gallery
Kobe beef is known as one of the three major types of wagyu beef in Japan. Kobe beef is, ostensibly, a title given to beef carefully selected from cattle named “Tajima beef.” Tajima beef, which is the root of brand beef, is judged after it becomes a carcass. Subsequently, an examination is conducted before it is put up for market auction, with only those that meet the very strict examination standards set by the Kobe Beef Marketing & Distribution Promotion Association being certified as Kobe beef. A true culinary treat for carnivores, it should be on everyone’s gastronomic radar. For fans of Kobe beef, The Kobe Beef Gallery is a facility that introduces its global appeal. Inside the museum, there are a wide variety of exhibits, including models, panels, and videos, and visitors can learn about the characteristics and production process of Kobe beef. In addition, visitors can taste and experience its quality while enjoying a meal.
https://kobebeef.gallery/

Yamaguchi Prefecture
Nagato Yumoto Onsen and Otanisanso Bettei Otozure
Nagato Yumoto Onsen, with a 600-year history, is a renowned hot spring once visited by samurai. Dubbed “Osoto Tengoku” (Outside Heaven), this area is perfect for exploration, offering picturesque pathways that lead to the soothing waters of ONTO ONSEN. Otanisanso Bettei Otozure, a luxury ryokan with 18 sumptuously designed rooms, features open-air hot spring baths and a Michelin-starred restaurant. Imbued in nature, these facilities, then, offer a serene retreat steeped in Japan’s hot spring culture.
https://yumotoonsen.com/

Tokushima Prefecture
Awa Ai indigo-Dyeing Experience
The Aizumicho Historical Museum, “Ai-no-Yakata,” showcases the history and techniques of Aizome (indigo dyeing), a traditional craft of Tokushima Prefecture. Indigo dyeing relies on the region’s clean water, and the museum preserves this heritage. Visitors can try Aizome and create distinctive pieces in a 40-minute session, with no reservations needed for individuals or small groups. This hands-on experience offers a rare chance to explore Tokushima’s rich history and craftsmanship. By participating, visitors gain insight into the deep cultural significance of Aizome and its traditional techniques, making it a unique and accessible cultural experience.
https://shikoku-guide.com/en/information/ainoyakata/

Ehime Prefecture
Castle Overnight Stay Experience
Ozu Castle Stay offers Japan’s first opportunity to stay in a fully restored castle keep, fusing history with luxury. Guests can immerse themselves in samurai culture through the “Lord of Ozu Castle” experience, dressing in armor and reenacting scenes from the era of Sadayasu Kato. The surrounding castle town retains its Edo-period charm, with highlights like Garyu Sanso, a historic villa with a serene garden along the Hiji River. This stay offers a rare blend of history, nature, and tradition.
https://castlestay.ozucastle.com/en/home

About Setouchi DMO:
The Setouchi DMO highlights the beauty, culture, and experiences of seven prefectures surrounding the Seto Inland Sea. It connects travelers with local events, and accommodations, promoting traditional culture, scenic landscapes, and regional cuisine while supporting local economic revitalization.

CONTACT: https://www.setouchi.travel/en/

Ultra Maritime Australia to provide world leading sonar on Hunter class frigates

ADELAIDE, South Australia, March 11, 2025 /PRNewswire/ — The Royal Australian Navy’s Hunter class frigates will be fitted with Ultra Maritime’s world-leading 2150 Bow Sonar under a contract with BAE Systems Maritime Australia (BAESMA). The delivery of the 2150 Bow Sonar will expand Australian sovereign undersea warfare capabilities, providing active and passive anti-submarine warfare (ASW) modes, mine and obstacle avoidance sonar, integrated underwater communications, and automated torpedo detection, classification and localization.

“Ultra Maritime is committed to building a strategic partnership with the Commonwealth of Australia, as we continue to invest and grow our support to the Royal Australian Navy fleet with delivery of world-class undersea warfare solutions,” said Mark Potter, Vice President and General Manager of Ultra Maritime Australia. “Our expertise in sonar, radar and electronic warfare, and torpedo defense will provide best-in-class capabilities within the maritime domain.”

Ultra Maritime has operated in Australia for more than 15 years, expanding from its indigenous electronic warfare capability to establish a sovereign sonar sustainment solution to support its Integrated Sonar System (ISS), as installed on the Hobart class air warfare destroyers (DDG). As Ultra Maritime’s Australian workforce continues to grow, we will continue to work closely with local industry to further maximize opportunities for Australian industry to assist with the Bow Sonar capability.

About Ultra Maritime

Ultra Maritime provides innovative multi-missions solutions for surface, sub-surface and unmanned platforms that protect and empower allied naval forces worldwide. Headquartered in Braintree, Massachusetts, Ultra Maritime employs more than 2,300 engineers and manufacturing experts worldwide, specializing in state-of-the-art sonar systems, radar, expendables, signature management and naval power systems. With major locations in the U.S., Canada, UK and Australia, Ultra Maritime is primed to support customers’ maritime missions around the globe.

Visit our website www.umaritime.com, and follow us on LinkedIn.